Lilly’s $1.3B Verve Buyout for Heart Therapy | Eli Lilly’s $1.3B Bet on Verve’s One-Shot Heart Disease Therapy
On June 17, 2025, Eli Lilly introduced a $1.3 billion acquisition of Verve Therapeutics, a biotech pioneering a one-time gene-editing remedy for coronary heart illness, boosting Verve’s inventory by 80%. The deal consists of $1 billion upfront ($10.50 per share) and as much as $300 million in contingent worth rights, payable if Verve’s lead … Read more